Analysis from continued follow-up of Phase 1/2 clinical trial data in Hunter syndrome (MPS II) reinforces potential for tividenofusp alfa (DNL310) to address full disease spectrumLaunch readiness ...

This paper presents a novel framework for optimizing Carbon Release (CR) through an AI-driven approach to Fossil Fuel Intake (FFI) management. We propose a new training methodology for AI models to ...

Shareholder/Analyst Call February 5, 2026 3:30 PM ESTCompany ParticipantsRyan Watts - Co-Founder, President, CEO ...

Brex reports that automated invoice processing enhances efficiency, reduces costs, minimizes errors, and improves cash flow ...

Fluence Energy, Inc. (Nasdaq: FLNC) ('Fluence” or the 'Company”), a global market leader delivering intelligent energy ...

Renewable energy sources supplied more than half of the quarterly energy demand in the National Electricity Market (NEM) for ...

Abu Dhabi's new Solar Self-Supply Policy aims to boost clean energy use and cut power demand by encouraging solar adoption ...

Mitie’s Net Zero Navigator shows decarbonisation delivers value when embedded in strategy, linking net zero to resilience, ...

Over the past three decades, the U.S. population soared by 28% and the economy more than doubled while its greenhouse emissions have remained about the same. A recent study explores the technical and ...

Designed to reinforce lucerastat as the first oral therapy suitable for all patients with Fabry disease, irrespective of their mutation type. The program is expected to support a potential regulatory ...

What begins as an effort to protect products often results in excess materials, inefficient transport and mounting ...

Allschwil, Switzerland - February 06, 2026Idorsia Ltd (SIX: IDIA) announces the design of its FDA-agreed Phase 3 registration program for lucerastat in Fabry disease. Building on the robust biomarker ...